Vaso's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Vaso (VASO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Vaso vs Its Competitors
- TTM: Trailing 12-month revenue of 80M vs 556,002M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-44.2% annualized vs trailing 12 months), vs accelerating (+2.6%) for its tracked peer group.
- Growth: Vaso generated -43.9% revenue growth year over year in Q2 2026, vs 8.6% for its competitors combined.
- Profitability: Its 4.9% net margin compares with 4.3% for the peer group.
- Scale: Vaso ranks #142 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
- Peer revenue share: Vaso accounted for 0.0% of combined revenue among its tracked peer group, down from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.28M compares with $1.11M for the peer group (0.3x).
- Structure: Vaso operates in the following segments: Professional Sales Service Segments, All Other Segments, Equipment Segments.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
VASO Sales vs. its Competitors, Q2 2026
Vaso reported revenue contraction of 43.94 % year on year in Q2 2026, below its competitors' combined revenue growth of 8.56 %.
With a net margin of 4.86 %, Vaso achieved higher profitability than its competitors (4.31 %).
Vaso generated 0.01 % of the combined sales of its peer group, down from 0.02 % a year earlier.
API endpoints for this dataset
Vaso vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Vaso reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Vaso and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Vaso Corporation | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Vaso's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.5% year over year, combined, vs -43.9% for Vaso. Vaso's share of combined industry revenue moved from 0.02% to 0.01%, a loss of 0.01 percentage points.
Vaso's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Vaso Corporation | Yes | No | No | No |
| Competitors combined (25) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 25.00 % (2 of 8) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
VASO Stock Performance relative to its Competitors
VASO Stock Performance relative to Similar-Size Competitors
VASO Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Becton Dickinson And Company | 282.9% | Outperformed |
| 2 | Pulmonx Corporation | 282.9% | Outperformed |
| 3 | Mckesson Corporation | 282.9% | Outperformed |
| 4 | Hologic Inc | 282.9% | Outperformed |
| 5 | Utah Medical Products Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Vaso's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Vaso Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Vaso Corporation |
51.14 | 80.22 |
 Medtronic Plc |
130,823.18 | 37,542.00 |
 Mckesson Corporation |
126,452.13 | 410,983.00 |
 Stryker Corp |
125,362.19 | 26,300.00 |
 Boston Scientific Corporation |
62,073.00 | 21,070.00 |
 Edwards Lifesciences Corporation |
58,996.06 | 6,512.50 |
| SUBTOTAL | 682,305.02 | 580,025.21 |
Sign in to see all competitors of Vaso Corporation.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Vaso Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Vaso's Competitors Named by the Company
Competitive relationships identified from Vaso reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Mckesson Corporation | Company report | 85% |
| Hologic Inc | Company report | 85% |
| Canon Inc | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Koninklijke Philips Nv | Company report | 85% |
| Utah Medical Products Inc | Company report | 85% |
| Ge Healthcare Technologies Inc | Company report | 85% |
| Procept Biorobotics Corporation | Company report | 85% |
| Angiodynamics Inc | Company report | 85% |
| Lemaitre Vascular Inc | Company report | 85% |
| Silk Road Medical Inc | Company report | 85% |
| Streamex Corp | Company report | 85% |
| Edwards Lifesciences Corporation | Company report | 85% |
| Atrion Corporation | Company report | 85% |
| Medtronic Plc | Company report | 85% |
| Stryker Corp | Company report | 85% |
| Adagio Medical Holdings inc | Company report | 85% |
| Merit Medical Systems Inc | Company report | 85% |
| Boston Scientific Corporation | Company report | 85% |
| Inari Medical Inc | Company report | 85% |
| Teleflex Incorporated | Company report | 85% |
Company report basis, confidence, active dates and source counts for Vaso's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Vaso's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vaso Corporation | Professional Sales Service Segments 93.81 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Mckesson Corporation | North American Pharmaceutical 82.34 % |
| Stryker Corp | MedSurg and Neurotechnology 56.20 % |
| Boston Scientific Corporation | Cardiovascular 66.29 % |
| Edwards Lifesciences Corporation | United States 58.74 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Vaso's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Vaso Corporation | 51 | 284,468 | 8,858 |
| Medtronic Plc | 130,823 | 395,179 | 55,463 |
| Mckesson Corporation | 126,452 | 8,058,490 | 103,922 |
| Stryker Corp | 125,362 | 469,643 | 64,696 |
| Boston Scientific Corporation | 62,073 | 357,119 | 59,220 |
| Edwards Lifesciences Corporation | 58,996 | 407,031 | 62,725 |
| PEERS TOTAL | 682,254 | 1,111,078 | 43,718 |
Vaso's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.92 % |
| Boston Scientific Corporation | United States 64.40 % |
| Becton Dickinson And Company | United States 61.88 % |
| Zimmer Biomet Holdings Inc | US 58.44 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Vaso's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Vaso's industry classification, broader than the peer set above. Market cap in millions of $.Vaso ranks #142 of 218 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 616, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 161,785 | 13.52 % |
| 2 | Medtronic Plc | 130,823 | 10.94 % |
| 3 | Stryker Corp | 125,786 | 10.51 % |
| 4 | 3m Company | 96,722 | 8.09 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Medline Inc | 1,234 | 5.2% |
| 142 | Vaso Corporation | 51 | 0.00 % |
Market cap and industry share for the rest of Vaso's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Vaso's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 137 | Inspiremd Inc | 59 | -70.57 % |
| 138 | Medinotec Inc | 59 | - |
| 139 | Alpha Pro Tech Ltd | 56 | 16.85 % |
| 140 | Positron Corporation | 55 | 12.84 % |
| 141 | Myomo Inc | 1,234 | 12.3% |
| 142 | Vaso Corporation | 51 | 141.67 % |
| 143 | Rosecliff Acquisition Corp I | 1,234 | 12.3% |
| 144 | Sensus Healthcare Inc | 1,234 | 12.3% |
| 145 | Tela Bio Inc | 1,234 | 12.3% |
| 146 | Precision Optics Corporation Inc | 1,234 | 12.3% |
| 147 | Star Equity Holdings Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Vaso's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Vaso's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 64.80 % | 46.17 % (avg) | +18.6 pp |
| Operating Margin | -2.00 % | industry median | -2.0 pp |
| EBITDA Margin | 1.71 % | -6.98 % (avg) | +8.7 pp |
| Capital Intensity (Capex / Revenue) | - | 7.18 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Vaso's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 38.2x | - |
| EV / EBITDA | 5.2x | 18.1x | -13.0x |
| P/B | 1.2x | 4.6x | -3.4x |
| Return on Equity | 8.65 % | industry aggregate | -3.33 % |
| Return on Invested Capital | -1.88 % | -6.82 % (avg) | 4.94 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Vaso's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 1.64 % | 2.39 % | -7.78 % | 8.20 % | 5.87 % | 1.63 % | 6.69 % | 2.68 % |
| Operating Margin | -5.03 % | 1.34 % | 1.11 % | 3.73 % | 8.79 % | 5.45 % | 0.33 % | -2.67 % |
| Return on Invested Capital | -16.67 % | 5.84 % | 3.37 % | 11.11 % | 16.58 % | 6.56 % | 0.41 % | -3.10 % |
| P/E | - | - | - | - | - | - | 62.9x | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Vaso's Strategic Group Map
Vaso is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Vaso's trailing-12-month revenue growth of -8.1% and operating margin of -2.0% compares with an average of -8.5% growth and -1.6% margin across its 8 closest peers by combined growth, margin and ROIC -- Vaso sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Vaso's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Vaso falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.9% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Vaso's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 616 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Vaso's dedicated Suppliers and Customers pages, not here.
Vaso's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Vaso falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Vaso's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-44.2% annualized vs trailing 12 months).
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Vaso's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Vaso Corporation | 0.81 | 1.64 | 0.01 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Mckesson Corporation | 0.07 | 0.88 | - |
| Stryker Corp | 0.50 | 2.08 | 0.65 |
| Boston Scientific Corporation | 0.23 | 1.50 | 0.46 |
| Edwards Lifesciences Corporation | 1.74 | 4.14 | 0.06 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Vaso's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Vaso Corporation | Q2 2026 | -43.9 % | - |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Mckesson Corporation | Q2 2026 | +7.7 % | +24.2 % |
| Stryker Corp | Q3 2026 | +7.6 % | -12.3 % |
| Boston Scientific Corporation | Q3 2026 | +1.4 % | -23.2 % |
| Edwards Lifesciences Corporation | Q2 2026 | +13.7 % | -27.2 % |
| PEERS TOTAL | +7.8 % | +49.6 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Vaso's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Vaso Corporation | Q2 2026 | -3.8 % | +0.0 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Mckesson Corporation | Q2 2026 | +7.6 % | -19.6 % |
| Stryker Corp | Q3 2026 | +3.0 % | +26.7 % |
| Boston Scientific Corporation | Q3 2026 | +12.3 % | -0.6 % |
| Edwards Lifesciences Corporation | Q2 2026 | +14.1 % | +35.7 % |
Vaso's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Vaso Corporation | 2.92% | 4.40% | 8.65% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Mckesson Corporation | 6.43% | 35.05% | - |
| Stryker Corp | 7.66% | 8.63% | 15.61% |
| Boston Scientific Corporation | 7.82% | 9.14% | 13.75% |
| Edwards Lifesciences Corporation | 7.41% | 8.39% | 9.65% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Vaso's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Vaso Corporation | 129.35 | 0.64 |
| Medtronic Plc | 299.41 | 3.48 |
| Mckesson Corporation | 28.51 | 0.31 |
| Stryker Corp | 34.70 | 4.77 |
| Boston Scientific Corporation | 18.14 | 2.95 |
| Edwards Lifesciences Corporation | 58.80 | 9.06 |
| PEERS AVERAGE | 29.90 | 1.18 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.